• aTyr Pharma

  Participated · Series E · Mar 2015

  aTyr Pharma is a San Diego-based biotherapeutics developer focused on therapeutics addressing severe and rare diseases, including muscular dystrophy. The company is advancing therapeutic programs targeted at those indications and other areas. In November 2016 the company secured additional financing in the form of a credit facility. The $20M facility was provided to improve the company’s near-term financial flexibility. aTyr said the proceeds will be used to pay off existing indebtedness and for general corporate purposes. No operational metrics or detailed program timelines were disclosed in the article. aTyr Pharma discovers and develops Therapeutics based on Physiocrines, naturally occurring extracellular signaling regions of tRNA synthetases, with a focus on immune-modulating treatments for rare diseases. Its lead clinical candidate, Resolaris, is an investigational Physiocrine-based drug currently in a Phase 1b/2 trial for facioscapulohumeral muscular dystrophy (FSHD). The company plans to use recent financing proceeds to advance Resolaris through clinical trials and to expand development into additional indications. aTyr has built an intellectual property estate of 24 issued patents and over 200 pending patent applications that it owns or exclusively licenses. The privately held biotech was founded by Professors Paul Schimmel and Xiang-Lei Yang of The Scripps Research Institute. In conjunction with the financing, aTyr added Srinivas Akkaraju, M.D., Ph.D., a general partner at Sofinnova Ventures, to its board of directors. aTyr Pharma is a San Diego-based developer of protein-based therapeutics focused on treatments for immune disorders. The company is advancing its first therapeutic program toward clinical development. The program is aimed at rare autoimmune diseases and a rare disease pipeline in immune disorders. aTyr said new financing will support that clinical development. The company is led by John Medlein. Specific terms of the financing were not disclosed. aTyr Pharma develops biologic therapeutics based on physiocrines, a recently elucidated class of endogenous human proteins. The company focuses on addressing diseases across blood, immune and metabolic disorders by advancing physiocrine drug candidates. aTyr raised $23M in a Series C equity financing to accelerate development of its preclinical pipeline and push candidates into clinical trials. The round was led by Domain Associates with participation from Alta Partners, Cardinal Partners and Polaris Ventures. The company was founded by Dr. Paul Schimmel and John Clarke. In conjunction with the financing, Dr. James C. Blair will join the board alongside John Clarke, Dr. David Mack, Dr. John Mendlein, Dr. Amir Nashat, Dr. Paul Schimmel and Dr. Jeff Watkins. aTyr Pharma is a San Diego-based company developing biopharmaceuticals focused on inflammation, autoimmune, hematopoietic, and metabolic disorders. On July 28, 2009, the company disclosed it had raised $12M in an additional funding round. The funding came from existing investors, including Alta Partners, Cardinal Partners, Polaris Ventures, and Paul Schimmel. That $12M was raised on top of $12M from the same venture backers in April 2007. No operating metrics, planned use of proceeds, or other financing terms were provided in the article.

• SteadyMed Therapeutics

  Led · Equity · Jan 2015

  SteadyMed develops therapeutic product candidates that address limitations of market-leading products in orphan and other well-defined, high-margin specialty markets. Its lead program, Trevyent, pairs the company’s PatchPump drug-delivery platform with treprostinil to treat pulmonary arterial hypertension (PAH). Trevyent is a development-stage product not approved by the FDA; SteadyMed intends to pursue approval via the 505(b)(2) regulatory pathway and to commercialize approved products using a targeted sales force. PatchPump is a compact, prefilled, preprogrammed, disposable parenteral administration platform designed to deliver sterile, preservative-free drug at a preset rate. The company operates offices in San Ramon, California and Rehovot, Israel. Financially, the company announced an equity financing to support regulatory and development milestones for Trevyent. SteadyMed Therapeutics develops drug products built around its PatchPump parenteral drug-delivery platform, targeting orphan and high-value diseases with unmet parenteral delivery needs. Its lead development program is Trevyent, a PatchPump-enabled, prefilled, preprogrammed disposable system to deliver treprostinil for Pulmonary Arterial Hypertension. The company plans to pursue approval via the 505(b)(2) regulatory pathway and to commercialize through a targeted SteadyMed sales and marketing infrastructure. SteadyMed said it has met with the FDA and received positive guidance on the registration pathway toward an NDA submission planned for the second half of 2015. The company intends to use proceeds to complete development and qualification activities to support that NDA and to build out outsourced manufacturing capabilities and industrialization partners for commercial supply. SteadyMed is a private, venture-funded company with offices in San Ramon, CA and Rehovot, Israel. SteadyMed Therapeutics develops the PatchPump, a prefilled, size-efficient and disposable electronic subcutaneous drug-delivery system that can be programmed to control delivery of liquid drugs across a range of volumes and viscosities. The company positions the PatchPump as a customizable family of devices intended to serve chronic conditions and to act as a delivery platform for large-volume biologics. SteadyMed has ongoing collaborations with biopharmaceutical companies that are evaluating the PatchPump for their large-volume biologics pipelines. The company is focused on completing clinical trials and obtaining FDA approval for its drug-plus-device combinations. SteadyMed is venture-backed by KB Partners and Samson Ventures and operates internationally with offices in the San Francisco Bay Area and Rehovot, Israel. Proceeds from recent financing are being used for working capital as it continues development and regulatory work toward commercialization. SteadyMed Therapeutics develops a novel, prefilled, size-efficient and disposable subcutaneous drug delivery system called PatchPump®. The company’s PatchPumps can be customized to deliver liquid drugs, including biologics, across a wide range of volumes and viscosities in a consistent and controllable manner. SteadyMed intends to use the proceeds from the financing to support development and commercialization of its lead drug product that leverages PatchPump® technology. The company is led by CEO Jonathan M.N. Rigby and operates from offices in San Francisco, CA and Rehovot, Israel. It aimed to complete pivotal clinical trials in 2013 with a planned commercial U.S. launch in 2014. The report states the company raised $10.4M in funding from existing and new backers to advance these plans.

No current team members are available.